Tesamorelin 5MG

Product Overview

Tesamorelin 5MG is a synthetic growth-hormone-releasing-hormone analogue research material, supplied as white to off-white lyophilised powder in a 5mg catalogue presentation (SKU TSM5). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

Tesamorelin research examines GHRH-receptor activation, growth-hormone and IGF-axis responses, and downstream metabolic endpoints under controlled study conditions.

Identity and Specifications

• Product: Tesamorelin 5MG
• SKU: TSM5
• Format: White to off-white lyophilised powder
• Synonyms: Tesamorelin, TH9507, GHRH analogue
• Catalogue purity specification: ≥99%
• CAS number: 218949-48-5
• Molecular formula: C221H366N72O67S
• Molecular weight: 5136 g/mol
• Amount: 5mg

Catalogue Distinction

This is the 5mg listing for this identity. The related Tesamorelin 10mg listing has a different labelled amount or volume and a separate SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• GHRH-receptor pharmacology
• growth-hormone and IGF-axis signalling
• body-composition and metabolic biomarkers in controlled studies
• assay design for endocrine-response research

Evidence Quality and Limitations

The literature includes controlled human studies, but the findings relate to defined clinical formulations and protocols. They do not validate the identity, sterility, stability or suitability of this independent research vial.

Storage and Handling

Before reconstitution: Published tesamorelin research-material instructions conflict between frozen storage and 2–8°C, and licensed medicinal formulations use different excipients. Follow the ExtolX batch-specific supplier documentation. If it does not state otherwise, keep the sealed lyophilised vial dry, protected from light and at −20°C or below as a conservative peptide-storage condition.

After reconstitution: No authoritative formulation-matched solution shelf life has been verified for this ExtolX batch. Validate the solvent, concentration, pH, container, temperature and hold time for the method. If the validated method supports frozen storage, use single-use aliquots and avoid repeated freeze–thaw cycles. Use clean laboratory technique, avoid vigorous agitation and record the preparation and storage history.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• Formulation-sensitive storage references: Vincerra research material, Moleculon specification sheet and DailyMed licensed formulation
• Randomised tesamorelin trial (PMID 23015655)
• Controlled metabolic study (PMID 28617838)
• Tesamorelin 10MG

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.